Navigation Links
FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
Date:11/5/2007

nd other targeted therapies have failed. With more than three years of clinical experience with Rexin-G in an increasing number of otherwise intractable cancers in the Philippines, Japan and the U.S., we have gained valuable insights into the general safety, optimal dosing parameters, and best treatment regimens that provide the greatest benefits for the cancer patient without compromising safety.

The on-going clinical trials of Rexin-G are centered in San Marino CA, where Epeius Biotechnologies Corporation has its headquarters, and in Santa Monica CA at the Sarcoma Oncology Center. Dr. Sant P. Chawla, M.D., who trained at the University of Texas M.D. Anderson Cancer Center, is a renowned expert on malignant sarcomas, and serves as Principal Investigator (PI) for these clinical trials.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. Credited with innovations ranging from oncogene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling platform technologies for the benefit of cancer patients worldwide. Rapid advances in clinical drug development provide Epeius with a unique opportunity for early revenues from the exportation and sale of its lead product to the Philippines and reciprocating Southeast Asian countries-thus demonstrating the high growth potential of a small biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.

To learn more about Rexin-G and Epeius' pipeline of proprietary compounds currently available for partnership or clinical trials, please visit
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... terms of duration of treatment and cost, patients ... accelerated partial breast irradiation (APBI) with proton therapy ... research from The University of Texas MD Anderson ... cost analysis study based on typical patient characteristics, ... charges for eight different types of partial and ...
(Date:10/31/2014)... 2014 Gold Medal Wine Club ... but tasteful gifts for the wine novice and enthusiasts on ... Gift Giving Special , which Early Bird shoppers receive discounts ... Club Gift membership. , Gift Givers must place their ... Besides offering discounts, Gold Medal Wine Club adds more value ...
(Date:10/31/2014)... scientists have found a drug combination that can trigger ... the way for new treatments, according to research that ... (NCRI) Cancer Conference in Liverpool next week*. , When ... chain of events culminating in self destruction. But cancer ... immortal. This means that cells grow out of control ...
(Date:10/31/2014)... October 31, 2014 Triple Board Certified ... hair restoration services to transform the appearance of military ... American Academy of Facial Plastic and Reconstruction Surgery (AAFPRS) ... to restore the facial hair Jones lost during an ... The pro-bono hair restoration procedure, valued around $16,000, took ...
(Date:10/31/2014)... Radiology and EMR Integration , “Surveys ... diagnostic imaging centers but Connectivity is Opportunity,” says ... “Differentiation is critical in all businesses today and ... the intense competition and the downward pressure on ... from the competition by fully integrating with the ...
Breaking Medicine News(10 mins):Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2Health News:Diagnostic Imaging of Salem Expects Growth Partnering with DigitalOne 2
... PhD, FNP Join Together to Raise Awareness of Common, ... Fibromyalgia is often called an "invisible" illness because ... sick. However, something as simple as a hug ... fibromyalgia is one of the most common chronic, widespread ...
... China, May 12 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, Inc., ... "Company"),(which recently changed its name from Genesis ... U.S. pharmaceutical company with its,principal operations in ... today,that its management will present at the ...
... Online Resource, YouCanBeTheOne.com, Recommended to Help Guide Important Conversations ... YORK, May 12 The multi-disciplinary expert consortium known ... calling upon family and friends to proactively start a ... physician at the first sign of possible Alzheimer,s disease ...
... Commissioned by Non-Profit Identifies Unmet Needs of CaregiversWASHINGTON, May ... Wellness Community revealed many Americans who provide support to ... as a caregiver. In fact, only 20 percent ... estimate of 60 percent. This year, it is projected ...
... and Pharma on PanelWALTHAM, Mass., May 12 ... ) announced today that CEO Lewis H. Bender will ... Markers in Drug Development: How Personalized Medicine is Evolving ... May 18-21, 2009 in Atlanta, GA. The panel ...
... DOYLESTOWN, Pa., May 12 The Quigley Corporation (Nasdaq: ... today announced that the world,s leading independent proxy advisory ... Glass Lewis & Co. have recommended that stockholders vote ... investor Ted Karkus, solicitation seeking control of the Board ...
Cached Medicine News:Health News:VIDEO from Medialink, the National Fibromyalgia Association and Pfizer: The Painful Truth about Fibromyalgia 2Health News:Jiangbo Pharmaceuticals, Inc. to Present at CCG IR's China Rising Conference in New York 2Health News:Jiangbo Pharmaceuticals, Inc. to Present at CCG IR's China Rising Conference in New York 3Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 2Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 3Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 4Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 5Health News:Cancer Caregiver Distress Unrecognized and Under Reported 2Health News:Cancer Caregiver Distress Unrecognized and Under Reported 3Health News:Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention 2Health News:Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention 3Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 2Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 3Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 4
(Date:10/30/2014)... -- Misonix, Inc. (NASDAQ: MSON ), an international ... innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and ... financial results for the first quarter fiscal year 2015 ... a conference call that same day, Thursday, November 6, ... Interested parties can access the conference ...
(Date:10/30/2014)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... the United States , today announced the ... Tel Aviv area of Israel.  ... of integrated R&D services to local customers. It will ...
(Date:10/30/2014)... , Oct. 30, 2014  Electronic health records ... a result of government initiatives and the considerable ... providers have invested over the past five years. ... health IT, and U.S. clinicians use them on ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & ...
Breaking Medicine Technology:Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4
... Aug. 8, 2011 Insmed Incorporated (Nasdaq CM: INSM), a ... six-months ended June 30, 2011. Key Recent ... of data from the open-label phase 2 study of Arikace™ ... (CF) patients with Pseudomonas lung infections ...
... (NYSE Amex: ANX ) today reported financial results ... we head into the second half of the year, we ... into the U.S. market, should it be approved on or ... Brian M. Culley, Chief Executive Officer of ADVENTRX.  "Having a ...
Cached Medicine Technology:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 2Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 3Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 4Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 5Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 6Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 7Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 8ADVENTRX Reports Second Quarter 2011 Financial Results 2ADVENTRX Reports Second Quarter 2011 Financial Results 3ADVENTRX Reports Second Quarter 2011 Financial Results 4ADVENTRX Reports Second Quarter 2011 Financial Results 5ADVENTRX Reports Second Quarter 2011 Financial Results 6ADVENTRX Reports Second Quarter 2011 Financial Results 7